Penile Cancer
More than 95% of penile cancers are squamous cell carcinoma of the glans/inner prepuce; management balances organ preservation against oncological control, and the single most important survival determinant is early, risk-adapted management of the inguinal lymph nodes.
The big picture
Penile cancer is an uncommon malignancy in industrialised countries but carries substantial morbidity and, in advanced disease, high mortality. More than 95% of penile cancers are squamous cell carcinomas (SCC), which usually arise from the epithelium of the inner prepuce or the glans. Management balances oncological control of the primary tumour against organ preservation, and hinges critically on early, risk-adapted management of the inguinal lymph nodes — the single most important determinant of survival.
Organ-sparing for the primary where feasible; risk-adapt the cN0 nodes on the T1a/T1b distinction (low-risk surveillance, high-risk invasive staging with DSNB); cN1–N2 → radical ILND (+ pelvic LND if ≥3 nodes or extranodal extension); cN3 → neoadjuvant chemotherapy then consolidative surgery; M1 → platinum-based chemotherapy (never bleomycin).
Mechanism pathway
Tap any step to see why it happens.
Interactive — penile cancer management (EAU)
Classification & subtypes
HPV-independent SCC
Includes the usual type (45–75% of cases; a diagnosis of exclusion, with variable differentiation), verrucous carcinoma (extremely well-differentiated, broad-based pushing front, with no metastasis reported), papillary, pseudohyperplastic, pseudoglandular, cuniculatum, sarcomatoid, and mixed subtypes.
- Why it matters:
- The sarcomatoid subtype (biphasic epithelial and spindle-cell neoplasia) is the most aggressive, with the worst prognosis — mortality up to 45–90%.
- Memory hook:
- p16 positivity is lower in HPV-independent SCC (≈17%).
- Board trap:
- Verrucous carcinoma is extremely well-differentiated with no metastasis reported.
HPV-associated SCC
Includes basaloid (uniform basaloid cells in nests/sheets, comedonecrosis), warty (condylomatous papillae with koilocytes), clear cell, lymphoepithelioma-like, and mixed (mainly warty-basaloid) subtypes.
- Why it matters:
- Roughly one-third to one-half of penile cancers are HPV-associated; p16 positivity is high in these morphologies (≈86%).
- Memory hook:
- p16 IHC is the practical surrogate for high-risk HPV when molecular testing is unavailable.
Treatment ladder
Organ-sparing treatment is preferred wherever feasible, with patients informed of the higher local-recurrence risk versus amputative surgery. For PeIN, options include topical 5-fluorouracil or imiquimod, or laser ablation (CO₂ or Nd:YAG); treatment effect is assessed after a treatment-free interval, and failed topical therapy should not be repeated. For invasive lesions confined to the glans/prepuce (Ta, T1–T2), organ-sparing surgery and reconstruction (circumcision, wide local excision, glansectomy, glans resurfacing) or radiotherapy (external-beam or brachytherapy) is offered to compliant patients under strict follow-up. Partial penectomy is offered for corpus cavernosum invasion (T3) or for patients unwilling/unable to undergo organ-sparing surgery or comply with follow-up. Total penectomy with perineal urethrostomy is reserved for large invasive tumours not amenable to partial amputation. For non-resectable advanced disease, induction chemotherapy followed by surgery in responders, or chemoradiotherapy, is offered.
Because occult nodal metastasis is present in a substantial minority of clinically node-negative patients, cN0 nodal management is risk-adapted. Low-risk (G1 pTa/pTis/pT1 without LVI/PNI — i.e. pT1a G1): the risk of metastasis is too low to justify surgical staging → surveillance. Intermediate-risk (pT1a G2): balance the risk of nodal metastasis against the morbidity of surgical staging on a case-by-case basis; surveillance may be discussed as an alternative. High-risk (≥pT1b — i.e. LVI, PNI, or poorly differentiated — or T2–T4): invasive nodal staging is recommended → dynamic sentinel node biopsy (DSNB); if DSNB is unavailable, perform ILND. Combine with ultrasound ± fine-needle aspiration cytology beforehand.
Radical inguinal lymph node dissection (rILND). Offer prophylactic ipsilateral pelvic lymphadenectomy if ≥3 inguinal nodes are involved on one side, or if extranodal extension is present. Complete inguinal and pelvic management within three months of diagnosis (unless neoadjuvant therapy is given).
Neoadjuvant chemotherapy followed by consolidative rILND + PLND to remove all residual disease in responders. Upfront surgery is discouraged given high morbidity and poor outcomes.
Platinum-based palliative chemotherapy (do not offer bleomycin, owing to pulmonary toxicity); palliative radiotherapy for symptom control; enrolment in clinical trials on progression.
Board traps
More than 95% of penile cancers are SCC, arising from inner prepuce/glans epithelium; the 2022 WHO classification is anchored on HPV status, with p16 IHC the practical surrogate.
HPV, phimosis, chronic inflammation, lichen sclerosus, and smoking are principal risk factors; roughly one-third to one-half of cases are HPV-associated.
The T1a vs T1b distinction (LVI, PNI, poor differentiation) drives cN0 nodal-risk stratification — low-risk surveillance, high-risk invasive staging with DSNB.
Nodal status is the dominant survival determinant: localised disease ≈81% five-year survival vs ≈16% with distant metastasis; ENE in even one node = pN3.
cN1–2 → rILND (+ pelvic LND if ≥3 nodes or ENE); cN3 → neoadjuvant chemo then consolidative surgery; M1 → platinum chemo (never bleomycin).